Brokerages Set Thermo Fisher Scientific Inc. (NYSE:TMO) Target Price at $618.94

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have been given a consensus rating of “Moderate Buy” by the eighteen analysts that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $618.94.

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group reissued a “buy” rating and set a $650.00 price objective (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. HSBC lifted their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Stifel Nicolaus boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Raymond James lifted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. The disclosure for this sale can be found here. Insiders have sold a total of 33,084 shares of company stock worth $19,767,092 over the last 90 days. Insiders own 0.34% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently modified their holdings of TMO. Boston Trust Walden Corp increased its stake in Thermo Fisher Scientific by 1.3% in the fourth quarter. Boston Trust Walden Corp now owns 2,155 shares of the medical research company’s stock valued at $1,144,000 after acquiring an additional 28 shares during the period. Arkadios Wealth Advisors increased its stake in shares of Thermo Fisher Scientific by 4.1% in the fourth quarter. Arkadios Wealth Advisors now owns 933 shares of the medical research company’s stock valued at $495,000 after buying an additional 37 shares in the last quarter. Allworth Financial LP boosted its position in shares of Thermo Fisher Scientific by 16.4% in the 4th quarter. Allworth Financial LP now owns 2,729 shares of the medical research company’s stock worth $1,448,000 after purchasing an additional 385 shares during the last quarter. Bank of Stockton acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $209,000. Finally, Nisa Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 129,501 shares of the medical research company’s stock valued at $68,738,000 after acquiring an additional 676 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Down 0.6 %

Shares of Thermo Fisher Scientific stock opened at $596.18 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $568.11 and a 200 day moving average price of $570.18. Thermo Fisher Scientific has a fifty-two week low of $415.60 and a fifty-two week high of $622.30. The firm has a market cap of $227.57 billion, a P/E ratio of 38.24, a P/E/G ratio of 2.80 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the firm posted $5.15 EPS. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, sell-side analysts forecast that Thermo Fisher Scientific will post 21.71 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be issued a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.